Minhong Tang

858 total citations · 1 hit paper
14 papers, 563 citations indexed

About

Minhong Tang is a scholar working on Oncology, Molecular Biology and Biotechnology. According to data from OpenAlex, Minhong Tang has authored 14 papers receiving a total of 563 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Molecular Biology and 3 papers in Biotechnology. Recurrent topics in Minhong Tang's work include Protein Degradation and Inhibitors (4 papers), Ubiquitin and proteasome pathways (3 papers) and Cancer-related Molecular Pathways (3 papers). Minhong Tang is often cited by papers focused on Protein Degradation and Inhibitors (4 papers), Ubiquitin and proteasome pathways (3 papers) and Cancer-related Molecular Pathways (3 papers). Minhong Tang collaborates with scholars based in Ireland, United Kingdom and South Korea. Minhong Tang's co-authors include John Crown, Michael J. Duffy, Shane O’Grady, Jianghui Meng, Jiafu Wang, Pia Herbolsheimer, Mark C. Lanasa, Christopher Gresty, Yvette Drew and Anita Wolfer and has published in prestigious journals such as Journal of Biological Chemistry, Biochemistry and Cancer Research.

In The Last Decade

Minhong Tang

13 papers receiving 561 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MYC as a target for cancer treatment

2021 296 citations Michael J. Duffy, Shane O’Grady et al. Cancer Treatment Reviews profile →

Peers

Countries citing papers authored by Minhong Tang

Since Specialization

Citations

This map shows the geographic impact of Minhong Tang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Minhong Tang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Minhong Tang more than expected).

Fields of papers citing papers by Minhong Tang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Minhong Tang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Minhong Tang. The network helps show where Minhong Tang may publish in the future.

Co-authorship network of co-authors of Minhong Tang

This figure shows the co-authorship network connecting the top 25 collaborators of Minhong Tang. A scholar is included among the top collaborators of Minhong Tang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Minhong Tang. Minhong Tang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Targeting MYC for the treatment of breast cancer: use of the novel MYC-GSPT1 degrader, GT19630 2025 ·Investigational New Drugs ·Minhong Tang, John Crown, (unknown)	1
2	MYC as a Target for Cancer Treatment: from Undruggable to Druggable? 2025 ·Targeted Oncology ·(unknown), Minhong Tang, John Crown	0
3	Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cells 2023 ·Investigational New Drugs ·Minhong Tang, John Crown, Michael J. Duffy	6
4	MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975 2022 ·Breast Cancer Research and Treatment ·Minhong Tang, Shane O’Grady, John Crown, Michael J. Duffy	25
5	Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use? 2022 ·Cancers ·Michael J. Duffy, Minhong Tang, (unknown), Shane O’Grady, John Crown	30
6	MYC as a target for cancer treatment breakdown → 2021 ·Cancer Treatment Reviews ·Michael J. Duffy, Shane O’Grady, Minhong Tang, John Crown	296
7	Abstract PD5-04: An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC) 2019 ·Cancer Research ·S. M. Domchek, Sophie Postel‐Vinay, S-A. Im, Winnie Yeo, J.P. Delord, Antoîne Italiano, Jérôme Alexandre, Benoît You, Susan E.P. Bastian, (unknown), Saiama N. Waqar, Mark C. Lanasa, (unknown), Minhong Tang, Christopher Gresty, (unknown), Pia Herbolsheimer, Bella Kaufman	16
8	Abstract OT3-05-03: MEDIOLA: An open-label, phase I/II basket study of olaparib (PARP inhibitor) and durvalumab (anti-PD-L1 antibody)–Additional breast cancer cohorts 2019 ·Cancer Research ·S. M. Domchek, Sophie Postel‐Vinay, S-A. Im, Y.H. Park, J.P. Delord, Antoîne Italiano, Jérôme Alexandre, Benoît You, Susan E.P. Bastian, (unknown), Saiama N. Waqar, Mark C. Lanasa, (unknown), Minhong Tang, Christopher Gresty, (unknown), Pia Herbolsheimer, Bella Kaufman	6
9	New Engineered-Botulinum Toxins Inhibit the Release of Pain-Related Mediators 2019 ·International Journal of Molecular Sciences ·Minhong Tang, Jianghui Meng, Jiafu Wang	17
10	An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC) 2018 ·Gynecologic Oncology ·Yvette Drew, Maja J.A. de Jonge, Sook Hee Hong, Y.H. Park, Anita Wolfer, Jennifer R. Brown, Michelle Ferguson, Martin Gore, Ricardo H. Álvarez, Christopher Gresty, Helen K. Angell, Kassondra Meyer, Maria Learoyd, Minhong Tang, Mark C. Lanasa, Pia Herbolsheimer, Susan M. Domchek	111
11	Neuronal entry and high neurotoxicity of botulinum neurotoxin A require its N-terminal binding sub-domain 2017 ·Scientific Reports ·Jiafu Wang, Jianghui Meng, (unknown), Minhong Tang, J. Oliver Dolly	13
12	Ligand-bound Structures and Site-directed Mutagenesis Identify the Acceptor and Secondary Binding Sites of Streptomyces coelicolor Maltosyltransferase GlgE 2016 ·Journal of Biological Chemistry ·Karl Syson, Clare E. M. Stevenson, (unknown), J. Elaine Barclay, Minhong Tang, (unknown), (unknown), David M. Lawson, Stephen Bornemann	10
13	Structural Insight into How Streptomyces coelicolor Maltosyl Transferase GlgE Binds α-Maltose 1-Phosphate and Forms a Maltosyl-enzyme Intermediate 2014 ·Biochemistry ·Karl Syson, Clare E. M. Stevenson, (unknown), Gerhard Saalbach, Minhong Tang, Anne Tuukkanen, Dmitri I. Svergun, Stephen G. Withers, David M. Lawson, Stephen Bornemann	28
14	Changes in biliary (high-molecular-mass) and liver isoforms of alkaline phosphatase after baboon-to-human liver transplantation 1994 ·Clinical Chemistry ·David F. Mercer, Minhong Tang, Ignazio R. Marino, A.J. Demetris, John J. Fung, Thomas E. Starzl, Vijay Warty	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact